STAT+: Lilly wins approval for once-weekly insulin shot
The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.
Eli Lilly has received approval for a groundbreaking once-weekly insulin shot, STAT+ reports. The story, brought to you by Jason Mast, covers recent developments in the biotech industry. In a separate development, the jury in California awarded Nektar Therapeutics $90 million in damages following a breach of contract dispute over the development of the autoimmune disease drug rezpeg.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
